Synapse - Kevin Curran

Results (14)

T-cell depleted peripheral blood stem cell (TCD-PBSC) transplants secure consistent engraftment with low risk of acute or chronic Gvhd and favorable disease free survival (DFS) and overall survival (OS) for pediatric patients (<21 years) with AML in CR1 or CR2 or MDS including tMDS/AML

Meeting Abstract

Kernan, N. A.; Boulad, F.; Prockop, S.; Wolden, S.; Scaradavou, A.; Kobos, R.; Lehrman, R.; Klein, E.; Curran, K. J.; Hasan, A. N.; more...
Blood (2015)

Fulltext@MSK | Save

Multi-center clinical trial of CAR T cells in pediatric/young adult patients with relapsed B-cell ALL

Meeting Abstract

Curran, K. J.; Riviere, I.; Silverman, L. B.; Kobos, R.; Shukla, N.; Steinherz, P. G.; Boulad, F.; Prockop, S.; Scaradavou, A.; Margossian, S. P.; more...
Blood (2015)

Fulltext@MSK | Save

Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL

Meeting Abstract

Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
Blood (2015)

Fulltext@MSK | Save

Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL

Meeting Abstract

Park, J.; Riviere, I.; Wang, X.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R.
Haematologica (2015)

Fulltext@MSK | Save

Management of late extraneural recurrence of medulloblastoma without high-dose chemotherapy

Journal Article

Phillips, R. E.; Curran, K. J.; Khakoo, Y.
Journal of Neuro-Oncology (2015)

Fulltext@MSK | Save

Phase I clinical trial of autologous CD19-targeted 19-28z CAR T cells in adult patients with Relapsed or refractory B-ALL

Meeting Abstract

Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Halton, E.; Quintanilla, H.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R. J.
Molecular Therapy (2015)

Fulltext@MSK | Save

Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)